^
Association details:
Biomarker:Chr del(5q)
Cancer:Myelodysplastic Syndrome
Regimen:VRD (bortezomib + dexamethasone injection + lenalidomide)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA

Published date:
05/11/2023
Excerpt:
We aim to report our experience with lenalidomide, bortezomib and dexamethasone therapy in a patient with MDS del(5q) and MM….She tolerated lenalidomide 10 mg daily, bortezomib 1.3 mg/m2 and dexamethasone once weekly of a 28-day cycle, with no treatment related complications. Reassessment of bone marrow following 6 cycles of treatment showed a partial response for MM and complete response for MDS.